Artery

Trading in Intershop shares temporarily suspended in connection with the implementation of the share split

Retrieved on: 
Wednesday, April 10, 2024
Geography, Artery, SIX Swiss Exchange

Trading in Intershop shares has temporarily been suspended yesterday, Thursday, 4 April 2024, and will be resumed for formal reasons after the share split on 10th April 2024 at the latest on a split basis.

Key Points: 
  • Trading in Intershop shares has temporarily been suspended yesterday, Thursday, 4 April 2024, and will be resumed for formal reasons after the share split on 10th April 2024 at the latest on a split basis.
  • Intershop is a real estate company listed on the SIX Swiss Exchange and active in Switzerland, which invests principally in commercial properties.
  • As of 31/12/2023, its portfolio included 43 properties with a lettable area of approx.
  • Intershop invests mainly in the Zurich area, around Lac Leman and along the main traffic arteries.

Annual General Meeting of Intershop Holding AG approves all proposals of the Board of Directors

Retrieved on: 
Wednesday, April 10, 2024
SIX Swiss Exchange, Artery, Intershop, CHF, Geography

71.35 percent of total shares respectively 92.11 percent of all shares registered in the share registrar with voting rights were represented at today's 61st Annual General Meeting of Intershop Holding AG.

Key Points: 
  • 71.35 percent of total shares respectively 92.11 percent of all shares registered in the share registrar with voting rights were represented at today's 61st Annual General Meeting of Intershop Holding AG.
  • All proposals tabled by the Board of Directors were approved.
  • During the subsequent meeting of the Board of Directors, Ernst Schaufelberger was appointed chairman of the Remuneration Committee.
  • Intershop is a real estate company listed on the SIX Swiss Exchange and active in Switzerland, which invests principally in commercial properties.

Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May

Retrieved on: 
Wednesday, April 10, 2024
Cholecalciferol, LDL, CRM, Cholesterol, Cardiovascular disease, Medicine, Digital, Dietary supplement, Business, Risk, Patient, Pharmacy, DSM-IV codes, ERP, Research, Stroke, Pharmacist, Business development, Executive Committee, HEART, Artery, Research and development, Omega-3 fatty acid, Safety, Enterocyte, Lipid metabolism, General practitioner, Marketing, Practitioner, Sleep, Hypercholesterolemia, Pharmaceutical industry

The natural and innovative characteristics of this product clearly position Valbiotis®PRO Cholestérol as a leader in the lifestyle and dietary management of hypercholesterolemia, a major risk factor for cardiovascular disease."

Key Points: 
  • The natural and innovative characteristics of this product clearly position Valbiotis®PRO Cholestérol as a leader in the lifestyle and dietary management of hypercholesterolemia, a major risk factor for cardiovascular disease."
  • Available behind the counter in pharmacies, the dietary supplement will also be sold without a prescription with a pharmacist’s recommendation.
  • It comprises a new generation of dietary supplements with active ingredients of natural origin, acting on several targets for comprehensive management.
  • A principal mechanism controls intestinal cholesterol absorption, while a complementary mechanism acts on hepatic metabolism for a comprehensive approach to the management of hypercholesterolemia.

Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases

Retrieved on: 
Wednesday, April 3, 2024
Hereditary hemorrhagic telangiectasia, Telangiectasia, Biotechnology, Blood, Disease, Atlas, Patient, Lung, Stroke, Viking Global Investors, Death, Artery, Chiari malformation, Rupture, Intraparenchymal hemorrhage, Heart failure, Lightspeed Venture Partners, Therapy, TGF, Antibody, Bleeding, Heart, Pharmacology, Unified school district, HHT, PAH, Atlas Venture, Pulmonary hypertension, Pharmaceutical industry

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched today with $128 million in financing. The Series A was co-led by BVF Partners and Atlas Venture, with participation from Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, Velosity Capital, and Checkpoint Capital. Diagonal was co-founded by Chief Executive Officer, Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital. The financing will support further advancement of the company’s proprietary DIAGONAL platform and pipeline of novel therapeutics to value-creating milestones, including its lead program for the treatment of hereditary hemorrhagic telangiectasia (HHT), a severely debilitating bleeding disorder with limited therapeutic options, through clinical proof-of-concept. Diagonal's agonist antibody activates a receptor complex in the TGF-β superfamily genetically impaired in HHT patients. In preclinical models of HHT, Diagonal's agonist antibodies prevent and reverse the formation of pathological vascular malformations.

Key Points: 
  • Diagonal was co-founded by Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital.
  • CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched today with $128 million in financing.
  • Diagonal was co-founded by Chief Executive Officer, Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital.
  • In preclinical models of HHT, Diagonal's agonist antibodies prevent and reverse the formation of pathological vascular malformations.

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

Retrieved on: 
Monday, April 8, 2024
Cardiovascular disease, Chest pain, Psoriasis, Coronary artery disease, Risk, Inflammation, Patient, Cardiovascular Research, Death, Plaque, Artery, American College, CCTA, Apolipoprotein, Heart, ACC, FAI, Pharmaceutical industry

ATLANTA, April 8, 2024 /PRNewswire/ -- Abcentra LLC, a clinical-stage biopharmaceutical company specializing in coronary artery disease, presented the latest results from a Phase 2a pilot, placebo-controlled, randomized clinical trial of Orticumab, a new drug with a novel mechanism of action to combat coronary inflammation, at the American College of Cardiology (ACC) Annual Scientific Sessions in Atlanta. The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.

Key Points: 
  • The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.
  • Orticumab is a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease.
  • Abcentra partnered with Caristo Diagnostics to leverage its CaRi-Heart AI technology to measure changes in patients' coronary artery inflammation as result of therapeutic intervention.
  • The results from this trial indicate that targeting oxLDL with Orticumab may reduce residual inflammatory risk and improve outcomes for patients with cardiovascular disease.

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

Retrieved on: 
Monday, April 8, 2024
Cardiovascular disease, Chest pain, Psoriasis, Coronary artery disease, Risk, Inflammation, Patient, Cardiovascular Research, Death, Plaque, Artery, American College, CCTA, Apolipoprotein, Heart, ACC, FAI, Pharmaceutical industry

ATLANTA, April 8, 2024 /PRNewswire/ -- Abcentra LLC, a clinical-stage biopharmaceutical company specializing in coronary artery disease, presented the latest results from a Phase 2a pilot, placebo-controlled, randomized clinical trial of Orticumab, a new drug with a novel mechanism of action to combat coronary inflammation, at the American College of Cardiology (ACC) Annual Scientific Sessions in Atlanta. The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.

Key Points: 
  • The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.
  • Orticumab is a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease.
  • Abcentra partnered with Caristo Diagnostics to leverage its CaRi-Heart AI technology to measure changes in patients' coronary artery inflammation as result of therapeutic intervention.
  • The results from this trial indicate that targeting oxLDL with Orticumab may reduce residual inflammatory risk and improve outcomes for patients with cardiovascular disease.

TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery

Retrieved on: 
Thursday, March 21, 2024
Vein, Consultant, Risk, Anatomy, Surgical mesh, Trauma, Chronic pain, Artery, Surgeon, AMS, FDA, Inguinal hernia, Suture

(NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of LIQUIFIX FIX8™ Laparoscopic and LIQUIFIX Precision™ Open Hernia Mesh Fixation Devices.

Key Points: 
  • (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of LIQUIFIX FIX8™ Laparoscopic and LIQUIFIX Precision™ Open Hernia Mesh Fixation Devices.
  • LIQUIFIX FIX8 is indicated for minimally invasive femoral and inguinal hernia repairs; and LIQUIFIX Precision is indicated for open femoral and inguinal hernia repairs.
  • The LIQUIFIX devices are the only FDA-approved devices that affix mesh and approximate peritoneal tissue with liquid anchors.
  • LIQUIFIX hernia mesh fixation devices eliminate the need for penetrating mechanical tacks, sutures, or staples by delivering a liquid adhesive that allows for precise and controlled mesh fixation.

Merit Medical Launches the Micro ACE™ Advanced Micro-Access System

Retrieved on: 
Tuesday, March 19, 2024
Food and Drug Administration, Blood, CE, Fluoroscopy, Atherosclerosis, Death, Plaque, United, Artery, MMSI, FDA, Health, Food, Electric motor

SOUTH JORDAN, Utah, March 19, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced commercial release of its US Food and Drug Administration (FDA)-cleared Micro ACE Advanced Micro-Access System.

Key Points: 
  • SOUTH JORDAN, Utah, March 19, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced commercial release of its US Food and Drug Administration (FDA)-cleared Micro ACE Advanced Micro-Access System.
  • Merit also intends to file Micro ACE for CE mark designation.
  • The Micro ACE system is the latest innovation in the Merit Vascular portfolio.
  • Combining a balance of stiffness and resiliency, Micro ACE is designed to achieve micro-access in a wide range of vascular anatomies.

Keep America Beautiful Kicks off the 2024 Great American Cleanup

Retrieved on: 
Tuesday, March 19, 2024
Blood pressure, Theft, Crime, Louisville, Kentucky, Public health, Recycling, Yuengling, Gardening, Beauty, McDonald's, Research, Violence, University, Volunteering, Artery, City, Plant, Michigan State University, Keep America Beautiful, Atmosphere, University of Louisville, Dow, Pet, Yosemite National Park, Air pollution, Tree, Homicide, Violent crime, Flower

Stamford, CT, March 19, 2024 (GLOBE NEWSWIRE) -- Keep America Beautiful® today officially kicks off its 2024 Great American Cleanup®, the annual spring-cleaning event in which 300,000 Americans are expected to take part in activities to pick up litter and green their communities between now and the first day of summer.

Key Points: 
  • Stamford, CT, March 19, 2024 (GLOBE NEWSWIRE) -- Keep America Beautiful® today officially kicks off its 2024 Great American Cleanup®, the annual spring-cleaning event in which 300,000 Americans are expected to take part in activities to pick up litter and green their communities between now and the first day of summer.
  • “Thanks to our amazing volunteers, we set a cleanup record in 2023, and we’re aiming to break that record in 2024,” said Keep America Beautiful President and CEO Jennifer Lawson.
  • But Keep America Beautiful officials say the impact of the cleanup goes far beyond simply making communities look nicer.
  • Sponsors for the 2024 Great American Cleanup include Altria, Cox, Diageo, Dow, McDonald's, Reynolds American, Santa Fe Natural Tobacco Company, and Yuengling.

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

Retrieved on: 
Tuesday, March 12, 2024
Consensus, Moyamoya disease, Cardiovascular disease, Myocardial infarction, Dyslipidemia, CVD, Cardiology, Risk, Patient, Apolipoprotein B, Consensus decision-making, Stroke, NAMS, ASCVD, Plaque, Artery, Diet, Cleveland Clinic, Ezetimibe, Clinical trial, Safety, FDC, Apolipoprotein, Genetic disorder, Physician, Pharmaceutical industry

NAARDEN, The Netherlands and MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the dosing of the first patient and initiation of TANDEM, a pivotal Phase 3 clinical trial to evaluate obicetrapib and ezetimibe FDC in adult patients with Heterozygous Familial Hypercholesterolemia (“HeFH”) and/or Atherosclerotic Cardiovascular Disease (“ASCVD”) or multiple risk factors for ASCVD, whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-modifying therapies.

Key Points: 
  • The ACC Expert Consensus set LDL-C goals of below the 70mg/dl for patients with ASCVD and below the 55mg/dl goal for ASCVD patients with very high risk.
  • The primary objective of the placebo-controlled, double-blind, four-arm, randomized TANDEM trial is to evaluate the effect of 10mg obicetrapib and 10mg ezetimibe FDC on LDL-C levels, compared to both ezetimibe 10mg and obicetrapib 10mg monotherapy and to placebo.
  • NewAmsterdam anticipates enrolling approximately 400 patients on maximally tolerated lipid-modifying therapies with HeFH, ASCVD or ASCVD risk equivalents and who have a baseline LDL-C of at least 70 mg/Dl.
  • Patients who have multiple risk factors for ASCVD are at high risk of experiencing a cardiovascular event in the near future.